Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

Tissue Regenix adds Chinese patent related to 'Meniscal Implants' to global exclusive licence portfolio

YORK, 28th April 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, has received the formal notice of allowance for a patent covering the use of its dCELL® technology for meniscal implants in the People's Republic of China.

The Group has exclusive access to a range of patents protecting its core process in major markets, and is adding to these by working with its technology partner, the University of Leeds, to protect individual products and processes.

Tissue Regenix's dCELL® decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient's body, and which can then be used to repair diseased or worn-out body parts. The latest patent covers the use of the dCELL® decellularisation process in creating meniscal implants to repair knee injuries.

Antony Odell, CEO of Tissue Regenix commented:"Tissue Regenix has always planned for a global roll-out of the dCELL® technology, and this patent covering the preparation of tissue for meniscal implantation in the People's Republic of China is an indicator that we are keen to include the rapidly growing Chinese soft tissue repair & sports medicine sector in our plans. Whilst the market is still relatively small, valued at approximately US$154m in 2011, (Source: iData Research), it 'holds a very high potential for future expansion' - according to the same report.

"Partial meniscectomies are the most common orthopaedic procedures undertaken globally, with around 61 per 100,000 population - and we see the market for dCELL® meniscus products continuing to grow to meet the needs of active individuals with sports injuries, and the ageing global population. This patent enables us to add China to the markets that we will target with our dCELL® products."

Tissue Regenix has offices in the UK & US and is concentrated on the global commercialisation of its dCELL® technology.

ENDS

For Further Information

Tissue Regenix Group Plc: +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

Newgate Communications: +44 207 6806550

Alistair Kellie

Andrew Jones

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.